FACT SHEET v1.0 · May 2026
Cancer Series

Upper tract urothelial cancer: the essentials

You have been told you have cancer in the lining of your renal pelvis or ureter. The medical name is upper tract urothelial carcinoma, or UTUC. It is the same cell type as bladder cancer. The location is what changes the plan. For the full story, see the Upper Tract Urothelial Cancer Patient Guide.

5 to 10%
Of all urothelial cancers start in the upper tract. The rest start in the bladder.
30 to 50
Out of 100 people get a bladder tumor at some point after UTUC. Most in the first 2 to 3 years.
1 in 3
Patients lose enough kidney work after surgery that the strongest chemo is no longer a fit.

Why the location changes the plan

The lining of your renal pelvis, your ureter, and your bladder is all the same tissue. Many of the words you may know from bladder cancer come up here too: papillary, low-grade, high-grade, recurrence. The wall up top is thinner, the kidney sits behind it, and the bladder lining stays after surgery. Those three differences are why the operation and the follow-up look different.

Low risk vs high risk

After your biopsy, scan, and urine cytology, your team places UTUC into one of two risk groups. The risk group drives the central choice: try to save the kidney, or take it out. Ask: "Is my UTUC low risk or high risk, and why?"

Low risk
All of these are true
  • Biopsy is low-grade
  • Looks papillary (small frond) on the scope or scan
  • One tumor, under about 2 cm
  • No deeper invasion on the scan
  • Not blocking the kidney
  • Urine cytology is not high-grade
High risk
Any one of these is true
  • Biopsy or cytology is high-grade
  • Tumor looks flat, not papillary
  • More than one tumor up top
  • 2 cm or larger
  • Blocking the kidney
  • Scan suggests invasion of nearby tissue
  • Past high-grade bladder cancer
Kidney-sparing care vs removing the kidney

Kidney-sparing (low risk)

Laser through a scope to destroy the tumor in place. Or remove a segment of the ureter and reconnect it. Repeat scopes at 3 months and beyond. The kidney stays. The visit schedule is long.

Jelmyto gel (low-grade)

A gel form of the chemo drug mitomycin C. Put into the renal pelvis through a thin catheter. Six weekly treatments. About 6 in 10 had a complete response at 3 months in the main trial. Main side effect: ureter narrowing.

Radical nephroureterectomy (high risk)

The standard high-risk operation. Removes the whole kidney, the entire ureter, and a small cuff of bladder on that side. Often called RNU. Done open, by laparoscopy, or by robot.

Chemo before or after RNU

For tumors into muscle or in lymph nodes, the POUT trial showed 4 cycles of platinum chemo after RNU lifted 3-year disease-free survival from 46% to 71%. Some centers now give chemo first, before kidney work drops.

If your other kidney is your only good one

If you have one working kidney already, or your other kidney is weak, keeping the affected side becomes a higher goal even when the cancer is high risk. Ask if staged scope treatment, segmental ureterectomy, or Jelmyto is a fit for you. A second opinion at a high-volume center makes sense here.

Lynch syndrome: ask about a gene test

UTUC is the urinary cancer most tied to Lynch syndrome, an inherited condition that raises risk of colon, uterine, and other cancers. About 1 to 3 out of 100 UTUC patients have it. Higher (5 to 9 in 100) if you were diagnosed under age 65 or have a family pattern. A positive test changes your other-cancer screens, your family's screens, and your drug options if the cancer ever spreads. Ask for a gene counselor referral if any of this fits you.

Surveillance goes on for years

Bladder scopes for life

The bladder lining stays after upper tract surgery. Cystoscopy at 3 months, then every 3 to 6 months for 2 years, then less often. For most people, this never fully stops.

Scans for the other side

About 8 to 13 out of 100 patients get a tumor in the opposite upper tract at some point. A belly and pelvis CT runs every 6 to 12 months for the first 2 to 3 years for high-risk disease, then yearly.

One dose of mitomycin after RNU

A single dose into the bladder within 2 weeks of surgery cuts bladder recurrence in the next year from about 32 in 100 to 17 in 100. Standard care when there is no reason not to give it.

Protect the kidneys you have

Watch blood pressure. Treat diabetes. Stay hydrated. Skip regular NSAIDs unless cleared. Get a yearly kidney lab test. Tell your team before any new pill or supplement.

Quit smoking, stay quit

Smoking causes about half of UTUC and drives recurrences. Patches, gum, varenicline, bupropion, counseling, and quit lines all work. Ask for a referral.

Watch herbal supplements

Plants in the Aristolochia family cause UTUC. If you take anything sold for "kidney support," weight loss, or "detox," bring the bottle to your next visit.

Questions to bring to your next visit
  • Is my UTUC low risk or high risk, and what features tipped it that way?
  • Am I a fit for kidney-saving care? Am I a fit for Jelmyto?
  • If I need RNU, what will my kidney function look like after, and will I still be a fit for cisplatin?
  • Should I see a cancer doctor before surgery or after? Is chemo first a fit for me?
  • Should I see a gene counselor for Lynch syndrome testing?
  • Has my case been reviewed at a tumor board? Would a second opinion at a high-volume center help here?
  • What does my next 12 to 24 months of follow-up look like? Can we put the dates on a calendar today?

Go to the ER for

You have heavy visible bleeding with clots. Your flank hurts badly and your temperature is above 100.4 F. You cannot urinate. Your belly hurts severely and you cannot keep anything down. You get new leg swelling, chest pain, or shortness of breath after surgery (possible blood clot). After a Jelmyto treatment: you run a high fever, have severe flank pain, or make clearly less urine on the treated side.

Call your team the same day for

You see blood in your urine between visits, even once. Your flank pain is new. Your treated side has new blockage symptoms. Side effects from chemo or Jelmyto interfere with your daily life. You missed a surveillance appointment and need help rescheduling.

Where to read more

For the full risk sort, kidney-sparing options side by side, the RNU walk-through, chemo timing, Lynch detail, surveillance schedule, and the metastatic drug options, see the Upper Tract Urothelial Cancer Patient Guide.